How long has retatrutide been studied?

How long has retatrutide been studied?

Retatrutide's earliest dated human enrollment is 18 December 2019, in a Phase 1b multiple-ascending-dose trial — a first-stage safety trial in which each group of volunteers received a series of gradually larger doses (Urva et al., The Lancet, 2022; NCT04143802). The compound was first described publicly in 2022 (Coskun et al., Cell Metabolism, 2022), and the retatrutide research guide traces that record forward; dated human research therefore runs from December 2019 to 2026. As of 2026 retatrutide is in Phase 3 trials.

Two kinds of date matter here, and they answer different questions. A registry date stamps when a trial enrolled people; a publication date stamps when the world could read about it. Retatrutide's registry record reaches back to December 2019, while its first journal paper landed in 2022 — so the compound was under study in humans for nearly three years before its name appeared in print. Both dates are real. They just measure different things.

Evidence limits

What does the research record not show?

Two widely quoted figures need their labels kept on. The 80-week and 104-week TRIUMPH-1 weight-change numbers are a company topline released by Eli Lilly on 21 May 2026 — a press release, not a peer-reviewed result. And the often-cited 24.2% body-weight change is the 48-week, 12-mg least-squares mean — a model-adjusted average — from 338 adults (Jastreboff et al., NEJM, 2023), not that trial's 24-week primary endpoint.

Comparisons also run ahead of the evidence. No published head-to-head trial of retatrutide against tirzepatide or semaglutide exists as of 2026, and TRIUMPH-5 (NCT06662383) is listed as active and not recruiting. The single published Phase 3 paper, TRANSCEND-T2D-1 (Bajaj et al., The Lancet, 2026), is a 40-week monotherapy trial in type 2 diabetes — retatrutide on its own, not added to another medicine — and not the obesity Phase 3 package. And the day-43 body-weight observation in the first characterization paper (Coskun et al., Cell Metabolism, 2022) is a single-dose Phase 1 pharmacodynamic measure — what the body did in response to one dose — not an efficacy result.

Even the headcounts disagree. The TRIUMPH-1 registry entry lists 2,335 participants enrolled, while Eli Lilly's 21 May 2026 company topline reports 2,339 randomised — figures from different counting points that are not interchangeable. The record does not resolve the gap, and neither does this article.

When did retatrutide first enter human trials?

Retatrutide's first dated human trial opened enrollment on 18 December 2019. That Phase 1b multiple-ascending-dose trial enrolled 72 people with type 2 diabetes, closing enrollment on 28 December 2020. The trial reported a half-life of about six days, which the paper describes as supporting a once-weekly schedule (Urva et al., The Lancet, 2022). An earlier Phase 1 single-ascending-dose study appears in the first characterization paper (Coskun et al., Cell Metabolism, 2022), but that record does not date its enrollment window — so 18 December 2019 remains the earliest dated human enrollment on record.

Read the two Phase 1 studies as a pair and a pattern shows up: the undated one came first, and the dated one built on it. Early safety work often surfaces later, folded into a characterization paper, which is exactly how the single-ascending-dose data reached print in 2022 (Coskun et al., Cell Metabolism, 2022). What the record does not permit is turning that gap into a date — human work on retatrutide was underway by 18 December 2019, and probably earlier, with the earlier part undated. The Phase 1b paper also recorded a week-12 body-weight change of up to −8.96 kg in the 3/6/9/12-mg group, once the placebo group's change was subtracted (Urva et al., The Lancet, 2022). The 90% confidence interval — the range the true figure most likely falls in — ran from −11.16 to −6.75. That is a signal measured over twelve weeks inside a safety trial, not an efficacy verdict.

What did the Phase 2 trials measure?

Two Phase 2 trials of retatrutide reported in 2023. In the obesity trial, 338 adults were followed for 48 weeks, and the 12-mg group averaged a 24.2% body-weight change against 2.1% on placebo (Jastreboff et al., New England Journal of Medicine, 2023). That trial's primary endpoint was the 24-week change, so 24.2% is a 48-week figure rather than the primary result. The diabetes trial randomised 281 participants across 42 US centres. HbA1c (a three-month blood-sugar marker) changed by 2.02 points to 24 weeks in the 12-mg escalation arm against 0.01 on placebo (Rosenstock et al., The Lancet, 2023).

A percentage only means something while it stays attached to the trial that produced it, so the details matter: 48 weeks, 338 adults, the 12-mg arm, and a placebo group that barely moved. At 48 weeks that same 12-mg group reached a body-weight change of 5% or more in 100% of participants, 10% or more in 93%, and 15% or more in 83%, against 27%, 9%, and 2% on placebo (Jastreboff et al., NEJM, 2023). The diabetes trial tells its own story — body weight at 36 weeks changed by −16.94% against −3.00% on placebo, with the dulaglutide 1.5-mg comparator arm posting an HbA1c change of −1.41 points (Rosenstock et al., The Lancet, 2023).

Numbers like these invite a league table, and the honest version of that comparison — same molecule versus approved medicine, with criteria stated and no ranking implied — lives in how retatrutide, Mounjaro, and Ozempic differ.

What stage is retatrutide at in 2026?

Retatrutide is in Phase 3 obesity trials as of 2026, run under a single master protocol — one trial design covering several sub-studies — registered as TRIUMPH-1 (ClinicalTrials.gov NCT05929066). That registry entry records an actual study start of 10 July 2023, an enrollment of 2,335 participants, and an actual study completion of 30 April 2026, with the results tab showing 'No Results Posted'. Eli Lilly published 80-week topline figures in a company press release on 21 May 2026 — a company topline, not a peer-reviewed trial result. The protocol pairs an 80-week main period with a 24-week extension, and the registry records an actual primary completion of 6 April 2026.

The topline figures come from Eli Lilly's 21 May 2026 company press release, not a journal. The release reports an 80-week efficacy estimand — the exact quantity a trial sets out to estimate — from an average baseline of 112.7 kg (BMI 40.0). Mean body-weight reductions were −28.3% in the 12-mg arm, −25.9% in the 9-mg arm, and −19.0% in the 4-mg arm, against −2.2% on placebo. A company topline arrives before the methods paper does, so these numbers sit in a different evidentiary class from everything in the citations list.

One wrinkle the registry cannot smooth out: ClinicalTrials.gov NCT05929066 lists 2,335 participants enrolled, while the 21 May 2026 Lilly company topline says 2,339 were randomised. Enrollment and randomisation are different counting points, neither source explains the gap, and both figures stand.

Has any Phase 3 result been published in a journal?

One Phase 3 trial of retatrutide has been published in a journal as of 2026. TRANSCEND-T2D-1 ran for 40 weeks in 537 adults with type 2 diabetes whose blood sugar was not controlled by diet and exercise alone (Bajaj et al., The Lancet, 2026). The trial ran across 48 sites, with randomisation to three retatrutide arms or placebo. TRANSCEND-T2D-1 measured blood-sugar control rather than obesity outcomes, so it sits outside the TRIUMPH obesity programme. The obesity programme's Phase 3 results have not appeared in a journal.

TRANSCEND-T2D-1 randomised its 537 participants to the 4-mg, 9-mg, and 12-mg arms or placebo — 134, 133, 136, and 134 respectively — and 490 completers, 91%, finished on drug (Bajaj et al., The Lancet, 2026). The same paper records HbA1c changes of −1.69%, −1.86%, and −1.94% across the three retatrutide arms against −0.81% on placebo, with body-weight changes of −11.5%, −13.9%, and −15.3% against −2.6% (Bajaj et al., The Lancet, 2026). Solid, peer-reviewed, Phase 3 — and aimed at blood sugar in type 2 diabetes, which is a different question from the one TRIUMPH-1 asks.

Is retatrutide approved anywhere?

Retatrutide holds no regulatory approval in any country as of 2026 — not from the FDA, not from the TGA, not from any other regulator — and remains an investigational compound. Research material is not a medicine, is not a substitute for one, and is not for human or animal use. Approval would require a completed Phase 3 evidence package assessed by a regulator, and the obesity Phase 3 registry entry shows no results posted as of 2026 (ClinicalTrials.gov NCT05929066).

What legally exists is laboratory reference material, sold for research use. Form Laboratories lists retatrutide reference material as freeze-dried laboratory stock with lot-matched paperwork — a certificate of analysis tied to a specific batch, which is not a medicine. Reading that paperwork is its own skill — what a certificate records, what a third-party report can and cannot prove, how a batch stays traceable — and the quality and verification hub walks through it.